Transcatheter aortic valve implantation compared with surgical aortic valve replacement in patients with anaemia

Abstract

<div lang="en" class="abs"><p class="abs_header">Abstract</p><p><em>Objectives:</em> We compared the outcome of anaemic patients undergoing transcatheter (TAVI) and surgical aortic valve replacement (SAVR) for severe aortic valve stenosis.</p><p><em>Methods:</em> Anaemic patients (haemoglobin <13.0 g/dL in men and <12.0 g/dL in women) undergoing TAVI and SAVR from the OBSERVANT study were the subjects of this analysis.</p><p><em>Results:</em> Preoperative anaemia was an independent predictor of 3-year mortality after either TAVI (HR 1.37, 95% CI 1.12–1.68) and SAVR (HR 1.63, 95% CI 1.37–1.99). Propensity score matching resulted in 302 pairs with similar characteristics. Patients undergoing SAVR had similar 30-d mortality (3.6% versus 3.3%, <em>p</em> = .81) and stroke (1.3% versus 2.0%, <em>p</em> = .53) compared with TAVI. The rates of pacemaker implantation (18.6% versus 3.0%, <em>p</em> < .001), major vascular damage (5.7% versus 0.4%, <em>p</em> < .001) and mild-to-severe paravalvular regurgitation (47.4% versus 9.3%, <em>p</em> < .001) were higher after TAVI, whereas acute kidney injury (50.7% versus 27.9%, <em>p</em> < .001) and blood transfusion (70.0% versus 38.6%, <em>p</em> < .001) were more frequent after SAVR. At 3-year, survival was 74.0% after SAVR and 66.3% after TAVI, respectively (<em>p</em> = .065), and freedom from MACCE was 67.6% after SAVR and 58.7% after TAVI, respectively (<em>p</em> = .049).</p><p><em>Conclusions:</em> These results suggest that TAVI is not superior to SAVR in patients with anaemia.</p></div>